Portal de Periódicos da CAPES

PNU‐99194A: A Preferential Dopamine D 3 Receptor Antagonist

1998; Wiley; Volume: 4; Issue: 1 Linguagem: Romeno

10.1111/j.1527-3458.1998.tb00040.x

1527-3458

Susanne R. Haadsma‐Svensson, Kjell Svensson,

Attention Deficit Hyperactivity Disorder

CNS Drug ReviewsVolume 4, Issue 1 p. 42-53 Free Access PNU-99194A: A Preferential Dopamine D3 Receptor Antagonist Susanne R. Haadsma-Svensson, Corresponding Author Susanne R. Haadsma-Svensson Pharmacia & Upjohn, Inc., Kalamazoo, MI, 49007 USAAddress correspondence and reprint requests to: S. Haadsma-Svensson, Structural, Analytic al & Medicinal Chemistry, Pharmacia & Upjohn, Inc., 7255-209-606, 301 Henrietta St., Kalamazoo, MI 49007, U S A.Search for more papers by this authorKjell A. Svensson, Kjell A. Svensson Pharmacia & Upjohn, Inc., Kalamazoo, MI, 49007 USASearch for more papers by this author Susanne R. Haadsma-Svensson, Corresponding Author Susanne R. Haadsma-Svensson Pharmacia & Upjohn, Inc., Kalamazoo, MI, 49007 USAAddress correspondence and reprint requests to: S. Haadsma-Svensson, Structural, Analytic al & Medicinal Chemistry, Pharmacia & Upjohn, Inc., 7255-209-606, 301 Henrietta St., Kalamazoo, MI 49007, U S A.Search for more papers by this authorKjell A. Svensson, Kjell A. Svensson Pharmacia & Upjohn, Inc., Kalamazoo, MI, 49007 USASearch for more papers by this author First published: 07 June 2006 https://doi.org/10.1111/j.1527-3458.1998.tb00040.xCitations: 25AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abbreviations: DA dopamine Ach acetylcholine SNPC substantia nigra pars compacta SNPR substantia nigra pars reticulata med. PFCx medial prefrontal cortex REFERENCES 1 Accili D, Fishburn CS, Drago J, et al. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 1996; 93: 1945– 1949. 2 Arneric SP, Roetker A, Long JP. Potent anorexic-like effects of RDS-127 (2-di-n-propylamino- 4,7-di-methoxyindane) in the rat: a comparison with other dopamine-receptor agonists. Neuropharmacology 1982; 21: 885– 890. 3 Arneric SP, Roetker A, Long JP, Mott J, Barfknecht CF. Effects of semirigid methoxamine analo gs on vascular smooth muscle: Studies of methoxy-2-aminotetralin and 2-aminoindane derivatives. Arch Int Pharmacodyn 1982; 257: 263– 273. 4 Baker LE, Miller ME, Svensson KA. Assessment of the discriminative stimulus effects of th e D3 dopamine antagonist PNU-99194A in rats: Comparison with psychomotor stimulants. Behav Pharmacol 1997; 8(2&3): 243– 252. 5 Bartoszyk GD. Anxiolytic effects of dopamine receptor ligands. 1. Involvement of dopamine autoreceptors. Life Sci March 1998; 62: 649– 663. 6 Bhatnagar RK, Arneric SP, Cannon JG, Flynn J, Long JP. Structure activity relationships of presynaplic dopamine receptor agonists. Pharmacol Biochem Behav (Suppl 1) 1982; 17: 11– 19. 7 Blanchet PJ, Konitsiotis S, Chase TN. Motor response to a dopamine D3 receptor-preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monk eys. J Pharmacol Exp Ther 1997; 283: 794– 799. 8 Caine SB, Koob GF. Pretreatment with the dopamine agonist 7-OH-DPAT shifts the cocaine self-administration dose-effect function to the left under different schedules in the rat. Behav Pharmacol 1995; 6: 333– 347. 9 Cannon JG, Perez JA, Bhatnagar RK, Long JP, Sharabi FM. Conformationally restricted cong eners of dopamine derived from 2-aminoindan. J Med Chem 1982; 25: 1442– 1446. 10 Clifford JJ, Waddington JL. Heterogeneity of behavioural profile between three new put ative selective D3 dopamine-receptor antagonists using an ethologically based approach. Psychopharmacology March 1998; 136: 284– 290. 11 Diaz J, Levesque D, Griffon N, et al. Opposing roles for dopamine D2 and D3 receptors on neurotensin mRNA expression in nucleus accumbens. Eur J Neurosci 1994; 6: 1384– 1387. 12 Ekman A. On dopamine D2and D3receptor pharmacology. Dissertation from the Department of Pharmacology, Göteborg University, Göteborg, Sweden. 1996, ISBN: 91-628-1913-5. 13 Flores G, Barbeau D, Quirion R, Srivastava LK. Decreased binding of dopamine D 3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. J Neurosci 1996; 16: 2020– 2026. 14 Franklin SR, Baker LE, Svensson KA. Discriminative stimulus properties of the dopamine D3 antagonist PNU-99194A. Psychopharmacology March 1998 (in press). 15 Gendreau PL, Petitto JM, Schnauss R, et al. Effects of the putative dopamine D3 receptor antagonist PNU-99194A on motor behavior and emotional reactivity in C57BL/6J mice. Eur J Pharmacol 1997; 337: 147– 155. 16 Gobert A, Rivet J-M, Audinot V, et al. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriata 1 pathways. J Pharmacol Exp Ther 1995; 275: 899– 913. 17 Griffon N, Diaz J, Levesque D, et al. Localization, regulation and role of the dopamine D3 receptor are distinct from those of the D2 receptor. Clin Neuropharmacol (Suppl 1) 1995; 18: S130– 142. 18 Griffon N, Pilon C, Sautel F, Schwartz J-C, Sokoloff P. Two intracellular signalling p athways for the dopamine D3 receptor: Opposite and synergistic interactions with cyclic AMP. J Neurochem 1997; 68: 1– 9. 19 Haadsma-Svensson SR, Smith MW, Lin C-H, et al. Synthesis and biological activity of C-5 modified derivatives of (+)-AJ76 and (+)-UH232: Increased dopamine D3 receptor preference and improved pharmacokinetic properties. Bioorg Med Chem Lett 1994; 4: 689– 694. 20 Hacksell U, Arvidsson L-E, Svensson U, et al. Monophenolic 2-(dipropylamino)indans and r elated compounds: Central dopamine receptor – stimulating activity. J Med Chem 1981; 24: 429– 434. 21 Hoffman WE, Hyslop DK, Piercey MF. Autoreceptors controlling SNPC dopamine neuron firin g are D3 dopamine receptors. Soc Neurosci Abstr 1996:#693.8. 22 Hoffman WE, Smith MW, Hyslop DK, Piercey MF. Electrophysiological evidence associati ng limbic preference with pramipexole, a D3-preferring dopamine agonist. Soc Neurosci Abstr 1995:#448.14. 23 Javed A, Rehman F, Heidenreich BA, Larson ER, Ariano MA, Napier TC. The functional pharmac ology of D3 receptors: Single neuron analysis on the ventral palladum. Soc Neurosci Abstr 1995:#448.13. 24 Kling-Petersen T. Effects of dopamine D2- and D3-receptor ligands on behavior and reward mechanisms. Dissertation from the Department of Pharmacology, Göteborg University, Göteborg, Sweden. 1994, ISBN: 91-628-1430-3. 25 Kling-Petersen T, Ljung E, Wollter L, Svensson K. Effects of dopamine D 3-preferring compounds on conditioned place preference and intracranial self-stimulation in the rat. J Neural Trans Gen Sec 1995; 101: 27– 39. 26 Kling-Petersen T, Ljung E., Svensson K. Effects on locomotor activity after local app lication of D3-preferring compounds in discrete areas of the rat brain. J Neural Trans Gen Sect 1995; 102: 209– 220. 27 Koeltzow TE, Xu M, Cooper DC, et al. Alterations in dopamine release but not dopamine autore ceptor function in dopamine D3 receptor mutant mice. J Neurosci March 1998; 18: 2231– 2238. 28 Kujacic M. Dopaminergic control of adrenomedullary function in the rat. 1994, ISBN: 91-628-1435-4. 29 Kujacic M, Svensson K, Lofberg L, Carlsson A. Dopamine receptors, controlling dopamine le vels in rat adrenal glands- comparison with central dopaminergic autoreceptors. J Neural Transm 1991; 84: 195– 209. 30 Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 1997; 49: 231– 252. 31 McMichael A, Walker EL, Piercey, MF. U-99194A, a D3 receptor antagonist, antagonizes brain energy metabolism evoked by the psychostimulant phencylidine (PCP): implications for antipsycho tic therapy. Soc Neurosci Abstr 1997:#747.14. 32 Merchant KM, Figur LM, Evans DL. Induction of c-fos mRNA in rat medial prefrontal cortex by antipsychotic drugs: role of dopamine D2 and D3 receptors. Cereb-Cortex 1996; 6: 561– 570. 33 Millan MJ, Peglion J-L, Vian J, et al. Functional correlates of dopamine D 3 receptor activation in the rat in vivo and their modulation by the selective antagonist (+)-S 14297: Activation of postsynapti c D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther 1995; 275: 885– 989. 34 Murray PJ, Harrison LA, Johnson MR, et al. A novel series of arylpiperazines with high affinity and selectivity for the dopamine D3 receptor. Bioorg Med Chem Lett 1995; 5: 219– 222. 35 Murray PJ, Helden RM, Johnson MR, et al. Novel 6-substituted 2-aminotetralins with potent and selective affinity for the dopamine D3 receptor. Bioorg Med Chem Lett 1996; 6: 403– 408. 36 Nichols NF, Virden TB, Svensson KA. Effects of (+)-MK801 on locomotor activity and prepu lse inhibition in rats: Comparison of potential antipsychotics between assays. Soc Neurosci Abstr 1997; 391: 17. 38 Piercey MF, Camacho-Ochoa M, Smith MW. Functional roles for dopamine-receptor subtypes. Clin Neuropharmacol 1995; 18: S34– S42. 39 Sautel F, Griffon N, Sokoloff P, et al. Nafadotride, a potent preferential dopamine D 3-receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther 1995; 275: 1239– 1246. 40 Scheel-Krüger J. The syndrome of sedation and yawning behaviour in the rat is dependent on postsynaptic D2 receptors. Psychopharmacology 1986; 89: S32. 41 Schmauss C, Haroutuninan V, Davis KL, Davidson M. Selective loss of dopamine D3 receptor mRNA expression in the parietal and motor cortex in patients with schizophrenia. Proc Nail Acad Sci USA 1993; 90: 8942– 8946. 42 Seeman P, VanTol HHM. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994; 15: 264– 270. 43 Sethy VH, Ellerbrock BR, Fici GJ, Wu H. D2 and D1 dopaminergic activity of 7-OH-DPAT. Brain Res 1996; 733: 41– 45. 44 Sokoloff P, Giros B, Martres M-P, Bouthenet M-L, Schwartz JC. Molecular cloning and characterization of a novel dopamine (D3) receptor as a target for neuroleptics. Nature 1990; 347: 146– 151. 45 Sokoloff P, Martres M-P, Giros B, Bouthenet M-L, Schwartz JC. The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem Pharmacol 1992; 43: 659– 666. 46 Stable L. Do autoreceptors mediate dopamine agonist-induced yawning and suppression of locomotion? A critical review. Psychopharmacology 1992; 106: 1– 13. 47 Steiner H, Fuchs S, Accili D. D3 dopamine receptor-deficient mouse: Evidence for reduced anxiety. Physiol Behav March 1998; 63: 137– 141. 48 Svensson KA, Franklin SR. Dopamine D3 and D4 receptors as potential therapeutic targets. In: P Jenner and R Demirdamar, eds. Dopamine receptor subtypes: from basic science to clinic. Amsterdam : IOS Press, March 1998: 147– 161. 49 Thorn L, Ashmeade TE, Storyey VJ, Routledge C, Reavill C. Evidence to suggest that agonist modulation of hyperlocomotion is via post-synaptic dopamine D2 or D3 receptors. Neuropharmacology 1997; 36: 787– 792. 50 Virden TB, Nichols NF, Baker LE, Svensson KA, Sutter DM. Effects of the novel D 3 antagonists (+)-AJ76 and PNU-99194A on apomorphine-induced disruption of prepulse inhibition. Soc Neurosci Abstr 1997:#747.4. 51 Walker EL, Smith MW, Schreur PJKD, Fitch CS, Piercey MF. U-99194A, A D 3-receptor antagonist, selectively abolishes amphetamine's non-striatal increases in brain energy metabolism: Implications for antipsychotic therapy. Soc Neurosci Abstr 1995:#341.15. 52 Waters N. On the functional role of the dopamine D3receptor. Dissertation from the Department of Pharmacology, Göteborg University, Göteborg, Sweden. 1995, ISBN: 91-628-1529-6. 53 Waters N, Lofberg L, Haadsma-Svensson S, Svensson K, Sonesson C, Carlsson A. Different ial effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement, and behavior. J Neural Transm 1994; 98: 39– 55. 54 Waters N, Svensson K, Haadsma-Svensson SR, Smith MW, Carlsson A. The dopamine D 3 receptor: A post-synaptic receptor inhibitory on rat locomotor activity. J Neural Transm 1993; 94: 11– 19. 55 Whetzel SZ, Shih YH, Geogic LM, Akunne HC, Pugsley TA. Effects of the dopamine D 3 antagonist PD 58491 and its interaction with the dopamine D3 agonist PD 128907 on brain dopamine synthesis in rat. J Neurochem 1997; 69: 2363– 2368. 56 Wright J, Downing D, Heffner T, Pugsley T, MacKenzie R, Wise L. Discovery of selective d opamine D3 ligands. Dimeric 2-(4-[3-aminopropoxy]phenyl)benzimidazole antagonists. Bioorg Med Chem Lett 1995; 5: 2541– 2546. 57 Xu M, Koeltzow TE, Santiago GT, et al. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron 1997; 19: 837– 848. Citing Literature Volume4, Issue1March 1998Pages 42-53 ReferencesRelatedInformation